In another long-term 26-week controlled trial, the incidence of EPS was 14.8% for aripiprazole-treated patients and 15.1% for olanzapine-treated patients.
Teises 26 nädalat väldanud kontrollrühmaga pikaajalises kliinilises uuringus oli EPS esinemus 14, 8% aripiprasooliga ja 15, 1% olansapiiniga ravitud patsientidel.